Korea Research Institute of Bioscience and Biotechnology

Yungjin Pharmaceutical Co., Ltd.

Dongguk University Industry-academic Cooperation Foundation

Korea Institute of Oriental Medicine

Enzychem Lifesciences Corporation

Ok-Kyoung Kwon

Kyung Seop Ahn

Sei Ryang Oh

Hyeong Kyu Lee

Sei-Ryang Oh

Doo-Young Kim

Dae-hee Shin

Byung-hwan Ryoo

Ji-seok Yoo

Yongnam Lee

Jung Hee Kim

Jung-hee Kim

Kyung-seop Ahn

Hyeongkyu Lee

Hyuk-hwan Song

Ji-Seok Yoo

Byung-Hwan Ryoo

Dae-Hee Shin

In Sik Shin

Seung Hyung Kim

Hyuk Hwan Song

Doo Young Kim

Hyung Won Ryu

Semi Kim

Su Ui Lee

Ha Young Jang

Mee-Young Lee

SuUi Lee

Hwa-Young Son

Kyoung-youl Lee

Hyuk-Hwan Song

Kyung-Seop Ahn

Suui Lee

Jung-Hee Kim

Kyeong Seok Lee

Jae Wha Kim

Sang Woo Lee

Ki Young Sohn

Hee Gu Lee

Ho Bum Kang

Tae-Suk Lee

Yong-Hae Han

Hyouk Joung

Seung Ho Kim

JongKoo Kang

Joongku Lee

Hang Jin

Wan Yi Li

Hye Kyung Kim

Hyun-Jun Lee

Soo Yong Kim

Da Jung Ji

Yoosik Yoon

Chan Mi Chun

Jang Mi Son

Byeong Hwa Jeon

Khiev Piseth

Xuezhen Xu

Giselle Tomayo-Castillo

Katia Rosales-Ovares

Rodrigo Gamez-Lobo

Hui Seong Kim

In-Sik Shin

Byoung Whui Choi

Ji Eun Yuk

Jongkoo Kang

The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-&#x3b1;, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.

Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating chronic obstructive pulmonary disease

A pharmaceutical composition includes any of an extract of, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-&#x3b1; and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.

Pharmaceutical composition for preventing and treating chronic obstructive lung disease containing, as active ingredient,extract, fraction, or active fraction thereof

A composition comprising a purified extract isolated fromvar.containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

Method of treating chronic obstructive pulmonary disease (CPD) with verproside

The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.

2-phenylbenzofuran derivatives, method for preparing the same and use of the same for treating inflammatory disease

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract ofvarthan that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

[object Object]

A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract ofvarthan that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and byextract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.

Asthma diagnosis using the neuropilin-1 gene, and method for screening for a therapeutic agent for asthma

The present invention relates to a pharmaceutical composition for treating wounds or revitalizing skin comprising theextract, the fractions thereof, or the diterpene compound isolated therefrom as an active ingredient. Theextract may act on epithelial cells to induce PKD1 activity required for improving the reproduction capability of differentiated epithelial cells, and thus may induce the phosphorylation of lower ERK1 and the generation of Cycline D, thus exhibiting an excellent ability to activate the reproduction of damaged skin. Therefore, theextract may be used effectively as an active ingredient in a pharmaceutical composition for treating wounds or reproducing skin, a health food for recovering skin damage or reproducing skin, or a functional cosmetic for inducing skin cell activity.

The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-&#x3b2;1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.

Composition containing styraxlignolide A or the aglycone thereof as an active ingredient for preventing or treating asthma

A pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma comprising the extract ofas an active ingredient. The extract ofof the present invention inhibited the increase of eosinophils in bronchoalveolar lavage fluid of the ovalbumin induced asthma animal model, had the activity of inhibiting the secretions of immunoglobulin and chemokine (Eotaxin) in bronchoalveolar lavage fluid and blood, and inhibited the secretions of NO and TNF-&#x3b1; in macrophages. Therefore, the extract ofof the present invention can be effectively used as an active ingredient of a pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma, and of a health functional food for the prevention and improvement of inflammatory disease or asthma.

Disclosed is a pharmaceutical composition for the prophylaxis and therapy of inflammatory diseases, allergic diseases, or asthma, comprising a velvet apple (A. DC.) extract as an active ingredient. Having the inhibitory activity against the nuclear translocation of NF-&#x3ba;B, whose level is rapidly elevated in response to inflammatory stimuli, the velvet apple extract can suppress the production of NO and PGE, the expression of iNOS and COX-2, and the release of IL-1&#x3b2; and TNF-&#x3b1;, and can significantly down regulate Th2-mediated IL-4 and IL-13 production. In addition, the extract was found to inhibit the activation of eosinophils in bronchoalveolar lavage fluid, and to suppress the secretion of immunoglobulins and chemokines in bronchoalveolar lavage fluid and blood, as measured by in vivo tests on an ovalbumin-induced asthma mouse model. Therefore, the extract can be used in the method for preventing or treating various inflammatory disorders, allergic diseases, or asthma.

Growing community of inventors

Daejeon, South Korea

Ok-Kyoung Kwon